Get the Stockscreener App
29.43
3.32%
0.945
After Hours:
29.40
-0.03
-0.10%
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $29.43, with a volume of 2.64M.
It is up +3.32% in the last 24 hours and up +2.51% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
See More
Previous Close:
$28.48
Open:
$28.6
24h Volume:
2.64M
Relative Volume:
0.76
Market Cap:
$1.42B
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-13.44
EPS:
-2.19
Net Cash Flow:
$-82.44M
1W Performance:
+8.98%
1M Performance:
+2.51%
6M Performance:
+45.05%
1Y Performance:
+76.86%
1-Day Range:
$28.33
$31.65
1-Week Range:
$26.10
$32.50
52-Week Range:
$8.79
$42.20
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
SAVA Stock Down On Settling Misleading Alzheimer's Study Data Claims - Barchart
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims - Yahoo Finance
Company News for Sep 30, 2024 - Yahoo Finance
SEC charges Cassava over 'misleading' Alzheimer's claims - pharmaphorum
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session - MSN
Cassava Sciences Sees Unusually Large Options Volume (NASDAQ:SAVA) - MarketBeat
(SAVA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava Sciences, Trump Media, and More - MSN
Why Cassava Sciences Stock Dived by Almost 11% Today - Yahoo Finance
Bristol Myers, Costco, EchoStar, DJT, Wynn, HP Inc., and More Stock Movers - Barron's
Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims - Yahoo Finance
Cassava Sciences shares drop in pre-open trade after $40 mln SEC settlement - MSN
Stocks to Watch Friday: Bristol-Myers Squibb, Costco, Cassava Sciences, EchoStar - The Wall Street Journal
Stocks making the biggest moves midday: Wynn Resorts, Rocket Lab USA, Cassava Sciences and more - CNBC
Cassava Sciences (NASDAQ:SAVA) Shares Gap Down to $31.87 - MarketBeat
Cassava Sciences Unusual Options Activity - Benzinga
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty - AOL
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims - Yahoo Finance
Cassava Sciences shares drop in pre-open trade after $40 mln SEC settlement - Investing.com
Cassava and SEC settle charges - The Pharma Letter
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty - Yahoo Finance
These Stocks Are Moving the Most Today: Costco, Bristol Myers, EchoStar, Cassava Sciences, Trump Media, and More - MSN
Cassava Sciences Shares Lower Premarket on $40M Penalty to Settle Doctored Data Claims - MarketWatch
Cassava settles SEC charges related to Alzheimer’s candidate for $40M (NASDAQ:SAVA) - Seeking Alpha
Bristol Myers, Costco, EchoStar, Cassava Sciences, DJT, and More Stock Market Movers - Barron's
Costco, Bristol Myers, EchoStar, Cassava Sciences, DJT, and More Stock Market Movers - Barron's
US charges Cassava Sciences, two former executives for misleading claims about Alzheimer’s clinical trial - WHBL
SEC Fines Cassava $40M Over Alzheimer's Treatment Claims - Law360
Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines - STAT
Stocks to Watch: Cassava Sciences, Scholastic, MeridianLink - MarketWatch
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims - Yahoo Finance
Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims - AOL
SEC Charges Cassava Sciences, Former Executives for Misleading Claims in Alzheimer's Trial - MarketWatch
Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims - Reuters
Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims - MarketWatch
Cassava Sciences Resolves SEC Investigation - GlobeNewswire
Cassava Sciences Resolves SEC Investigation - EIN News
Cassava’s Simufilam: Safe On The Outside, Scrambled On The Inside (NASDAQ:SAVA) - Seeking Alpha
Cassava Sciences (NASDAQ:SAVA) Shares Up 3.7% - MarketBeat
Why I'm Avoiding Cassava Stock For Now (NASDAQ:SAVA) - Seeking Alpha
Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials - Benzinga
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials - GlobeNewswire
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials - Yahoo Finance
Cassava Sciences Unusual Options Activity For September 23 - Benzinga
Bank of New York Mellon Corp Buys 21,558 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) - MarketBeat
Cassava Sciences (NASDAQ:SAVA) Shares Down 3.8% - MarketBeat
Cassava Sciences stock gains on pact with ex-CEO (NASDAQ:SAVA) - Seeking Alpha
Cassava Sciences (NASDAQ:SAVA) Trading Up 10.8% - MarketBeat
(SAVA) Technical Pivots with Risk Controls - Stock Traders Daily
What's Going On With Cassava Sciences Today? - MSN
Cassava Sciences names new CEO, separates chairman role - Investing.com
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):